July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Pars plicata versus pars plana application of micropulse transscleral cyclophotocoagulation
Author Affiliations & Notes
  • Sören Waibel
    Universit�tsaugenklinik Dresden, Dresden, Germany
  • Robert Herber
    Universit�tsaugenklinik Dresden, Dresden, Germany
  • Lutz E Pillunat
    Universit�tsaugenklinik Dresden, Dresden, Germany
  • Karin R Pillunat
    Universit�tsaugenklinik Dresden, Dresden, Germany
  • Footnotes
    Commercial Relationships   Sören Waibel, None; Robert Herber, None; Lutz Pillunat, None; Karin Pillunat, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 706. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sören Waibel, Robert Herber, Lutz E Pillunat, Karin R Pillunat; Pars plicata versus pars plana application of micropulse transscleral cyclophotocoagulation. Invest. Ophthalmol. Vis. Sci. 2019;60(9):706.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study was to compare the efficacy and safety of transscleral micropulse cyclophotocoagulation (MPC) applied at the level of the pars plicata (PLI-MPC) versus at the pars plana (PLA-MPC).

Methods : In this prospective interventional case series, 45 eyes of 29 medically treated open-angle gaucoma patients scheduled for MPC (IRIDEX IQ810 Laser Systems, CA) for further IOP reduction were included. Twenty-seven eyes underwent PLI-MPC and 18 eyes PLA-MPC. Twenty-four hour mean intraocular pressure (IOP) reduction 3 months after the procedure, and complications were compared between both groups. Statistical analyses were performed with SPSS. Pre- and postoperative IOP differences between the two treatment groups were carried out using a linear mixed model.

Results : In the PLI-MPC group (mean age: 75.41 ± 5.92 years), 24 hour mean IOP was reduced from 15.8 ± 2.9 mmHg to 13.9 ± 2.9 mmHg at 3 months (P=0.005). In the PLA-MPC group (mean age: 75.17 ± 8.67 years), mean IOP decreased from 16.5 ± 3.3 mmHg to 14.0 ± 2.8 mmHg (P=0.003). No complications were reported in either group. There were no correlations between IOP reduction and age, gender, high or normal pressure glaucoma or the severity of the visual field.

Conclusions : PLI-MPC and PLA-MPC seem to be safe and effective in lowering the IOP of patients with treated open-angle glaucoma. Both modes of application showed a statistically significant IOP lowering.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×